Polymerase chain response (PCR) is by far probably the most generally used methodology of nucleic acid amplification and has likewise been employed for a plethora of diagnostic functions. Nonetheless, multiplexed PCR-based detection schemes have hitherto been largely restricted by technical challenges related to nonspecific interactions and different limitations inherent to conventional fluorescence-based assays.
Right here, we describe a novel technique for multiplexed PCR-based evaluation known as Ligation-eNabled fluorescence-Coding PCR (LiNC PCR) that exponentially enhances the multiplexing functionality of ordinary fluorescence-based PCR assays. The approach depends upon a easy, preliminary ligation response by which goal DNA sequences are transformed to PCR template molecules with distinct endpoint fluorescence signatures.
Common TaqMan probes are used to create target-specific multicolor fluorescence alerts that may be readily decoded to establish amplified targets of curiosity. We exhibit the LiNC PCR approach by implementing a two-color-based assay for detection of 10 ovarian most cancers epigenetic biomarkers at analytical sensitivities as little as 60 template molecules with no detectable goal cross-talk. General, LiNC PCR gives a easy and cheap methodology for reaching high-dimensional multiplexing that may be carried out in manifold molecular diagnostic functions.
Effectivity of the novel quenching-probe PCR methodology to detect 23S rRNA mutations in kids with Mycoplasma pneumoniae an infection
An automatic speedy molecular diagnostic equipment (Sensible Gene Myco) was just lately developed for particular person detection of Mycoplasma pneumoniae (MP) genes. This new testing strategy requires no particular gear and abilities and will be accomplished inside 50 min. We prospectively evaluated this diagnostic equipment, together with different typical checks, for pneumonia analysis in kids.
Samples from 98 kids (50 boys and 48 ladies; aged 1-14 years; imply: 4.7 ± 2.1 years; median: Four years) clinically identified with pneumonia had been examined for MP utilizing real-time polymerase chain response (RT-PCR) as a reference methodology. Outcomes from three molecular diagnostic checks, serum anti-MP antibodies, and MP tradition had been in comparison with RT-PCR information.
Among the many 98 kids, 38 had been optimistic for MP. All molecular diagnostic outcomes confirmed full concordance with the RT-PCR information. The sensitivity of the tradition was 64%, whereas the sensitivities of the ImmunoCard Mycoplasma and SERODIA Myco II kits had been decrease (39% and 29%, respectively). Moreover, a major optimistic correlation was discovered between MP copy numbers and the tradition take a look at sensitivity (r = 0.95, p = 0.048).
Macrolide-resistance mutations within the 23S ribosomal RNA gene had been detected in 24 of 38 kids utilizing Sensible Gene Myco based mostly on quenching-probe PCR, which was confirmed by direct sequencing, revealing all mutations as A2063G. That is the primary examine to judge the medical utility of the Sensible Gene Myco equipment, demonstrating that it’s a quick and dependable methodology to help well timed therapeutic choices in kids with MP pneumonia.
Arboviruses within the Astrakhan area of Russia for 2018 season: The event of multiplex PCR assays and evaluation of mosquitoes, ticks, and human blood sera
The Astrakhan area of Russia is endemic for the variety of arboviruses. On this paper, we describe the outcomes of the detection of the listing of uncared for arboviruses within the Astrakhan area for the 2018 season. For the aim of the examine in-house PCR assays for detection of 18 arboviruses have been developed and validated utilizing arboviruses obtained from Russian State Assortment of Viruses.
Swimming pools of ticks (n = 463) and mosquitoes (n = 312) in addition to 420 samples of human sufferers sera have been collected and analyzed. Utilizing developed multiplex real-time PCR assays we had been in a position to detect RNA of eight arboviruses (Crimean-Congo hemorrhagic fever virus, Dhori (Batken pressure) virus, Batai virus, Tahyna virus, Uukuniemi virus, Inkoo virus, Sindbis virus and West Nile fever virus). All found viruses are able to infecting people inflicting fever and in some circumstances extreme kinds with hemorrhagic or neurologic signs.
From PCR-positive samples, we had been in a position to get well one isolate every of Dhori (Batken pressure) virus and Crimean-Congo hemorrhagic fever virus which had been additional characterised by next-generation sequencing. The genomic sequences of recognized Dhori (Batken pressure) virus pressure signify probably the most full genome of Batken virus pressure amongst beforehand reported.
Haplotype-specific PCR for NAT2 diplotyping
N-acetyltransferase 2 (NAT2) is an enzyme that acetylates many sorts of medicine, together with the antituberculosis drug isoniazid. The NAT2 gene is extremely various throughout populations. A person will be categorised as having a sluggish acetylator (SA), an intermediate acetylator (IA), or a speedy acetylator (RA) phenotype based mostly on its two haplotypes (diplotype) of NAT2. SA people are at the next danger for isoniazid-induced hepatitis, whereas the RA phenotype contributes to failure in tuberculosis therapy.
With the ability to predict particular person NAT2 phenotypes is necessary for dose adjustment of isoniazid. NAT2 haplotypes are generally decided by way of an oblique methodology of statistical haplotype inference from SNP genotyping. Right here, we report a direct NAT2 haplotyping methodology utilizing haplotype-specific PCR (HS-PCR) for the 6 mostly discovered NAT2 haplotypes: NAT2*4, NAT2*5B, NAT2*6A, NAT2*7B, NAT2*12A, and NAT2*13A. Validation of this HS-PCR methodology by way of comparability with a sequencing methodology in 650 Thai DNA samples (107 RA, 279 IA, and 264 SA samples) confirmed a concordance charge for diplotype calls of 99.23% (645/650 samples).
CP-640186 |
|||
| 9422-25 | Biovision | each | EUR 666 |
CP-640186 |
|||
| 9422-5 | Biovision | each | EUR 222 |
CP-466722 |
|||
| A8625-10 | ApexBio | 10 mg | EUR 136 |
|
Description: ATM inhibitor,potent and reversible |
|||
CP-466722 |
|||
| A8625-5 | ApexBio | 5 mg | EUR 88 |
|
Description: ATM inhibitor,potent and reversible |
|||
CP-466722 |
|||
| A8625-50 | ApexBio | 50 mg | EUR 374 |
|
Description: ATM inhibitor,potent and reversible |
|||
CP-91149 |
|||
| A8403-10 | ApexBio | 10 mg | EUR 105 |
|
Description: Selective inhibitor of glycogen phosphorylase |
|||
CP-91149 |
|||
| A8403-25 | ApexBio | 25 mg | EUR 210 |
|
Description: Selective inhibitor of glycogen phosphorylase |
|||
CP-91149 |
|||
| A8403-5 | ApexBio | 5 mg | EUR 63 |
|
Description: Selective inhibitor of glycogen phosphorylase |
|||
Coelenterazine CP |
|||
| 10112 | Biotium | 50uG | EUR 77 |
|
Description: N/A |
|||
Coelenterazine CP |
|||
| 10112-1 | Biotium | 1MG | EUR 77 |
|
Description: N/A |
|||
Coelenterazine CP |
|||
| 10112-1-1 | Biotium | EA | EUR 831 |
Coelenterazine CP |
|||
| 10112-2 | Biotium | 250uG | EUR 257 |
|
Description: N/A |
|||
Coelenterazine CP |
|||
| 10112-2-1 | Biotium | EA | EUR 257 |
CP-690550 |
|||
| 1622-25 | Biovision | each | EUR 738 |
CP-690550 |
|||
| 1622-5 | Biovision | each | EUR 255.6 |
CP-609754 |
|||
| 206096 | MedKoo Biosciences | 10.0mg | EUR 450 |
CP-547632 |
|||
| 200810 | MedKoo Biosciences | 5.0mg | EUR 300 |
CP-724714 |
|||
| 200820 | MedKoo Biosciences | 5.0mg | EUR 250 |
CP-346086 |
|||
| 471083 | MedKoo Biosciences | 5.0mg | EUR 270 |
CP-335963 |
|||
| 471085 | MedKoo Biosciences | 1.0g | EUR 170 |
CP-101537 |
|||
| 471091 | MedKoo Biosciences | 10.0mg | EUR 90 |
CP Antibody |
|||
| 46543 | SAB | 100ul | EUR 319 |
CP Antibody |
|||
| 46543-100ul | SAB | 100ul | EUR 302.4 |
CP Antibody |
|||
| 45875-100ul | SAB | 100ul | EUR 302.4 |
CP Antibody |
|||
| 45875-50ul | SAB | 50ul | EUR 224.4 |
CP 135807 |
|||
| 413313 | MedKoo Biosciences | 5.0mg | EUR 275 |
CP Antibody |
|||
| E046543 | EnoGene | 100μg/100μl | EUR 255 |
|
Description: Available in various conjugation types. |
|||
CP Antibody |
|||
| DF9369 | Affbiotech | 200ul | EUR 420 |
CP Antibody |
|||
| DF9369-100ul | Affinity Biosciences | 100ul | EUR 280 |
CP Antibody |
|||
| DF9369-200ul | Affinity Biosciences | 200ul | EUR 350 |
CP Antibody |
|||
| E19-9369-1 | EnoGene | 50ug/50ul | EUR 145 |
|
Description: Available in various conjugation types. |
|||
CP Antibody |
|||
| E19-9369-2 | EnoGene | 100ug/100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
CP-466722 |
|||
| B1722-1 | Biovision | each | EUR 183.6 |
CP-466722 |
|||
| B1722-5 | Biovision | each | EUR 418.8 |
CP-547632 |
|||
| B2056-500 | Biovision | each | EUR 183.6 |
CP 135807 |
|||
| B7497-10 | ApexBio | 10 mg | EUR 270 |
|
Description: 5-HT1D receptor agonist |
|||
CP 135807 |
|||
| B7497-50 | ApexBio | 50 mg | EUR 1096 |
|
Description: 5-HT1D receptor agonist |
|||
CP 775146 |
|||
| B7609-10 | ApexBio | 10 mg | EUR 308 |
|
Description: PPARα agonist |
|||
CP 775146 |
|||
| B7609-50 | ApexBio | 50 mg | EUR 1234 |
|
Description: PPARα agonist |
|||
CP 80633 |
|||
| B7162-10 | ApexBio | 10 mg | EUR 258 |
|
Description: PDE4 inhibitor |
|||
CP 80633 |
|||
| B7162-50 | ApexBio | 50 mg | EUR 1019 |
|
Description: PDE4 inhibitor |
|||
CP 154526 |
|||
| B7185-1 | ApexBio | 1 mg | EUR 48 |
|
Description: CRF1 receptor antagonist |
|||
CP 154526 |
|||
| B7185-5 | ApexBio | 5 mg | EUR 78 |
|
Description: CRF1 receptor antagonist |
|||
CP 96345 |
|||
| B7213-10 | ApexBio | 10 mg | EUR 285 |
|
Description: NK1 receptor antagonist |
|||
CP 96345 |
|||
| B7213-50 | ApexBio | 50 mg | EUR 1163 |
|
Description: NK1 receptor antagonist |
|||
CP-424174 |
|||
| B2531-1 | Biovision | each | EUR 157.2 |
CP-424174 |
|||
| B2531-5 | Biovision | each | EUR 405.6 |
CP-544326 |
|||
| B1121-25 | Biovision | each | EUR 666 |
CP-544326 |
|||
| B1121-5 | Biovision | each | EUR 222 |
CP-724714 |
|||
| B1333-25 | Biovision | each | EUR 940.8 |
CP-724714 |
|||
| B1333-5 | Biovision | each | EUR 314.4 |
CP-673451 |
|||
| B1337-1 | Biovision | each | EUR 288 |
CP-673451 |
|||
| B1337-5 | Biovision | each | EUR 810 |
CP-673451 |
|||
| B2173-10 | ApexBio | 10 mg | EUR 180 |
|
Description: PDGFRα/β inhibitor,potent and selective |
|||
CP-673451 |
|||
| B2173-200 | ApexBio | 200 mg | EUR 1672 |
|
Description: PDGFRα/β inhibitor,potent and selective |
|||
CP-673451 |
|||
| B2173-5 | ApexBio | 5 mg | EUR 95 |
|
Description: PDGFRα/β inhibitor,potent and selective |
|||
CP-673451 |
|||
| B2173-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 128 |
|
Description: PDGFRα/β inhibitor,potent and selective |
|||
CP-673451 |
|||
| B2173-50 | ApexBio | 50 mg | EUR 543 |
|
Description: PDGFRα/β inhibitor,potent and selective |
|||
CP 316819 |
|||
| B5448-10 | ApexBio | 10 mg | EUR 298 |
|
Description: Selective glycogen phosphorylase inhibitor |
|||
CP 316819 |
|||
| B5448-50 | ApexBio | 50 mg | EUR 1185 |
|
Description: Selective glycogen phosphorylase inhibitor |
|||
CP 20961 |
|||
| B5474-10 | ApexBio | 10 mg | EUR 226 |
|
Description: non-immunogenic adjuvant |
|||
CP 20961 |
|||
| B5474-50 | ApexBio | 50 mg | EUR 952 |
|
Description: non-immunogenic adjuvant |
|||
CP-640186 |
|||
| B3585-10 | ApexBio | 10 mg | EUR 156 |
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
|||
CP-640186 |
|||
| B3585-2 | ApexBio | 2 mg | EUR 64 |
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
|||
CP-640186 |
|||
| B3585-5 | ApexBio | 5 mg | EUR 96 |
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
|||
CP-640186 |
|||
| B3585-50 | ApexBio | 50 mg | EUR 616 |
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
|||
CP-10447 |
|||
| C781200 | Toronto Research Chemicals | 10mg | EUR 201 |
|
Description: 843-93-6 |
|||
CP 96345 |
|||
| C781210 | Toronto Research Chemicals | 250mg | EUR 9200 |
|
Description: 132746-60-2 |
|||
(±)-CP 55940 |
|||
| C781225 | Toronto Research Chemicals | 0.5mg | EUR 1518 |
CP-141938 |
|||
| C781290 | Toronto Research Chemicals | 100mg | EUR 12800 |
|
Description: 182822-62-4 |
|||
CP-316819 |
|||
| C781300 | Toronto Research Chemicals | 10mg | EUR 356 |
CP-471474 |
|||
| C781305 | Toronto Research Chemicals | 5mg | EUR 86 |
|
Description: 210755-45-6 |
|||
CP-47497 |
|||
| C781310 | Toronto Research Chemicals | 10mg | EUR 69 |
(-)-CP-47947 |
|||
| C781325 | Toronto Research Chemicals | 25mg | EUR 31000 |
|
Description: 114753-51-4 |
|||
CP-775146 |
|||
| C781355 | Toronto Research Chemicals | 10mg | EUR 230 |
|
Description: 702680-17-9 |
|||
CP-91149 |
|||
| C781360 | Toronto Research Chemicals | 100mg | EUR 76 |
|
Description: 186392-40-5 |
|||
CP 724714 |
|||
| C781365 | Toronto Research Chemicals | 250mg | EUR 4500 |
|
Description: 383432-38-0 |
|||
CP-466722 |
|||
| C781395 | Toronto Research Chemicals | 10mg | EUR 1200 |
|
Description: 1080622-86-1 |
|||
CP-481715 |
|||
| C781405 | Toronto Research Chemicals | 100mg | EUR 9200 |
|
Description: 212790-31-3 |
|||
(+)-CP 55940 |
|||
| C781415 | Toronto Research Chemicals | 25mg | EUR 27000 |
|
Description: 83002-05-5 |
|||
CP 640186 |
|||
| C591780 | Toronto Research Chemicals | 100mg | EUR 4500 |
|
Description: 591778-68-6 |
|||
CP Antibody |
|||
| CAC09179-100ug | Biomatik Corporation | 100ug | EUR 314 |
CP Antibody |
|||
| CAC09179-50ug | Biomatik Corporation | 50ug | EUR 199.2 |
CP-226269 |
|||
| 513641 | MedKoo Biosciences | 5.0mg | EUR 275 |
CP-105696 |
|||
| 524768 | MedKoo Biosciences | 5.0mg | EUR 265 |
CP-55940 |
|||
| 524805 | MedKoo Biosciences | 10.0mg | EUR 600 |
CP 66713 |
|||
| 524810 | MedKoo Biosciences | 5.0mg | EUR 280 |
CP-471474 |
|||
| 524847 | MedKoo Biosciences | 10.0mg | EUR 295 |
CP-532623 |
|||
| 524851 | MedKoo Biosciences | 5.0mg | EUR 300 |
CP-673451 |
|||
| 524866 | MedKoo Biosciences | 5.0mg | EUR 350 |
CP-868388 |
|||
| 524879 | MedKoo Biosciences | 5.0mg | EUR 320 |
CP-91149 |
|||
| 524881 | MedKoo Biosciences | 10.0mg | EUR 240 |
CP-809101 |
|||
| A3330-10 | ApexBio | 10 mg | EUR 138 |
|
Description: 5-HT2C receptor agonist |
|||
CP-809101 |
|||
| A3330-50 | ApexBio | 50 mg | EUR 591 |
|
Description: 5-HT2C receptor agonist |
|||
CP-724714 |
|||
| A2412-100 | ApexBio | 100 mg | EUR 589 |
|
Description: HER2 inhibitor,potent and selective |
|||
CP-724714 |
|||
| A2412-25 | ApexBio | 25 mg | EUR 235 |
|
Description: HER2 inhibitor,potent and selective |
|||
CP-724714 |
|||
| A2412-5 | ApexBio | 5 mg | EUR 68 |
|
Description: HER2 inhibitor,potent and selective |
|||
CP-724714 |
|||
| A2412-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 74 |
|
Description: HER2 inhibitor,potent and selective |
|||
CP 471474 |
|||
| A4435-10 | ApexBio | 10 mg | EUR 201 |
|
Description: Broad spectrum MMP inhibitor |
|||
CP 471474 |
|||
| A4435-50 | ApexBio | 50 mg | EUR 842 |
|
Description: Broad spectrum MMP inhibitor |
|||
CP-380736 |
|||
| 561663 | MedKoo Biosciences | 5.0mg | EUR 255 |
CP-96345 |
|||
| 562171 | MedKoo Biosciences | 5.0mg | Ask for price |
CP siRNA |
|||
| 20-abx912716 | Abbexa |
|
|
CP siRNA |
|||
| 20-abx912717 | Abbexa |
|
|
CP Antibody |
|||
| 1-CSB-PA14599A0Rb | Cusabio |
|
|
|
Description: A polyclonal antibody against CP. Recognizes CP from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
CP-640186 |
|||
| T1889-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-640186 |
|||
CP-640186 |
|||
| T1889-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: CP-640186 |
|||
CP-640186 |
|||
| T1889-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: CP-640186 |
|||
CP-640186 |
|||
| T1889-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: CP-640186 |
|||
CP-640186 |
|||
| T1889-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: CP-640186 |
|||
CP-724714 |
|||
| T4014-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-724714 |
|||
CP-724714 |
|||
| T4014-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: CP-724714 |
|||
CP-724714 |
|||
| T4014-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: CP-724714 |
|||
CP-724714 |
|||
| T4014-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: CP-724714 |
|||
CP-724714 |
|||
| T4014-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: CP-724714 |
|||
CP-628006 |
|||
| T40386-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-628006 |
|||
CP-628006 |
|||
| T40386-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: CP-628006 |
|||
CP-628006 |
|||
| T40386-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: CP-628006 |
|||
CP-628006 |
|||
| T40386-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: CP-628006 |
|||
CP-628006 |
|||
| T40386-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: CP-628006 |
|||
CP-610431 |
|||
| T40675-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-610431 |
|||
CP-610431 |
|||
| T40675-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: CP-610431 |
|||
CP-610431 |
|||
| T40675-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: CP-610431 |
|||
CP-610431 |
|||
| T40675-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: CP-610431 |
|||
CP-610431 |
|||
| T40675-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: CP-610431 |
|||
CP Antibody |
|||
| ABD9369 | Nova Lifetech | 100ug | EUR 325 |
CP 471474 |
|||
| A4435-1 | ApexBio | 1mg | EUR 40 |
|
Description: Proteases|MMP |
|||
CP 471474 |
|||
| A4435-5 | ApexBio | 5mg | EUR 104 |
|
Description: Proteases|MMP |
|||
CP-724714 |
|||
| GW3270 | Glentham Life Sciences | 1mg | EUR 432.95 |
CP Antibody |
|||
| F50324-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 322.15 |
|
Description: Ceruloplasmin is a metalloprotein that binds most of the copper in plasma and is involved in the peroxidation of Fe(II) transferrin to Fe(III) transferrin. Mutations in this protein cause aceruloplasminemia, which results in iron accumulation and tissue damage, and is associated with diabetes and neurologic abnormalities. |
|||
CP-724714 |
|||
| MBS131447-100mg | MyBiosource | 100mg | EUR 1495 |
CP-91149 |
|||
| MBS131451-100mg | MyBiosource | 100mg | EUR 1065 |
CP-91149 |
|||
| MBS131451-500mg | MyBiosource | 500mg | EUR 2775 |
CP-547632 |
|||
| MBS131064-100mg | MyBiosource | 100mg | EUR 1065 |
CP-547632 |
|||
| MBS131064-500mg | MyBiosource | 500mg | EUR 2775 |
CP 640186 |
|||
| MBS130359-100mg | MyBiosource | 100mg | EUR 1065 |
CP 640186 |
|||
| MBS130359-500mg | MyBiosource | 500mg | EUR 2775 |
CP 673451 |
|||
| MBS132201-100mg | MyBiosource | 100mg | EUR 1065 |
CP 673451 |
|||
| MBS132201-500mg | MyBiosource | 500mg | EUR 2775 |
CP 724714 |
|||
| MBS132265-100mg | MyBiosource | 100mg | EUR 1065 |
CP 724714 |
|||
| MBS132265-500mg | MyBiosource | 500mg | EUR 2775 |
CP-945598 |
|||
| MBS132331-100mg | MyBiosource | 100mg | EUR 1065 |
CP-945598 |
|||
| MBS132331-500mg | MyBiosource | 500mg | EUR 2775 |
CP-724714 |
|||
| GW3270-1 | Glentham Life Sciences | 1 | EUR 171.5 |
CP-724714 |
|||
| GW3270-10 | Glentham Life Sciences | 10 | EUR 401.4 |
CP-724714 |
|||
| GW3270-5 | Glentham Life Sciences | 5 | EUR 254 |
CP-673451 |
|||
| HY-12050 | MedChemExpress | 5mg | EUR 283.2 |
CP-547632 |
|||
| HY-13302 | MedChemExpress | 10mM/1mL | EUR 160.8 |
CP 316311 |
|||
| HY-14129 | MedChemExpress | 1mg | EUR 1018.8 |
CP 376395 |
|||
| HY-14130 | MedChemExpress | 10mg | EUR 366 |
CP-724714 |
|||
| HY-14674 | MedChemExpress | 100mg | EUR 1242 |
CP-640186 |
|||
| HY-15259 | MedChemExpress | 100mg | EUR 1299.6 |
CP-809101 |
|||
| HY-15543 | MedChemExpress | 50mg | EUR 854.4 |
CP-66948 |
|||
| HY-19048 | MedChemExpress | 20mg | EUR 5763.6 |
CP-96486 |
|||
| HY-100316 | MedChemExpress | 1mg | EUR 2128.8 |
CP 375 |
|||
| HY-100332 | MedChemExpress | 1mg | EUR 1870.8 |
CP-466722 |
|||
| HY-11002 | MedChemExpress | 50mg | EUR 753.6 |
CP-28888 |
|||
| HY-U00008 | MedChemExpress | 5mg | EUR 1960.8 |
CP-060 |
|||
| HY-U00354 | MedChemExpress | 5mg | EUR 4292.4 |
CP 465022 |
|||
| P398988 | Toronto Research Chemicals | 100mg | EUR 3000 |
|
Description: 199655-36-2 |
|||
CP-28888 |
|||
| T10868-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-28888 |
|||
CP-28888 |
|||
| T10868-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: CP-28888 |
|||
CP-28888 |
|||
| T10868-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: CP-28888 |
|||
CP-28888 |
|||
| T10868-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: CP-28888 |
|||
CP-28888 |
|||
| T10868-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: CP-28888 |
|||
CP-409092 |
|||
| T10869L-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-409092 |
|||
CP-409092 |
|||
| T10869L-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: CP-409092 |
|||
CP-409092 |
|||
| T10869L-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: CP-409092 |
|||
CP-409092 |
|||
| T10869L-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: CP-409092 |
|||
CP-409092 |
|||
| T10869L-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: CP-409092 |
|||
CP-547632 |
|||
| T10870L-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-547632 |
|||
CP-547632 |
|||
| T10870L-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: CP-547632 |
|||
CP-547632 |
|||
| T10870L-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: CP-547632 |
|||
CP-547632 |
|||
| T10870L-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: CP-547632 |
|||
CP-547632 |
|||
| T10870L-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: CP-547632 |
|||
CP-96486 |
|||
| T10873-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: CP-96486 |
|||
The discordant ends in 5 samples had been resulting from Three uncommon NAT2 haplotypes: NAT*5C (n = 3), NAT2*7C (n = 1), and NAT2*11A (n = 1). This novel HS-PCR methodology permits direct NAT2 diplotyping, enabling the implementation of NAT2 acetylator phenotypes in medical pharmacogenetic testing.